Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy

d2_banpc.jpg d2_banph.jpg

Pipeline

Product

Target

Indication

Commercial Rights

Preclinical

IND-Enabling

Phase l

Phase ll

Phase lll

  • RBD4059

    (RiboGalSTARTM)​

    FXI

    Thrombotic Diseases

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • RBD5044

    (RiboGalSTARTM)​

    APOC3

    Hypertrigly-
    ceridemia

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • RBD7022

    (RiboGalSTARTM)​

    PCSK9

    Hypercho-
    lesterolemia​

    Global
     (ex-China) *

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • RBD7007

    (RiboGalSTARTM)​

    C5

    Renal Diseases

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • RBD2080

    (RiboGalSTARTM)​

    Undisclosed

    Renal Diseases

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • RBD1119

    (RiboGalSTARTM)​

    Undisclosed

    Thrombotic Diseases

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • RBD6096

    (RiboGalSTARTM)​

    Undisclosed

    Thrombotic Diseases

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • RBD4094

    (RiboGalSTARTM)​

    Undisclosed

    Dyslipidemia

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • SR122​

    (RiboGalSTARTM)​

    Dual Targets​

    Dyslipidemia

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

  • RBD3103

    (RiboPepSTARTM)​

    Undisclosed​

    Renal Diseases

    Global

    Preclinical

    IND-Enabling

    Phase l

    Phase ll

    Phase lll

* In December 2023, we granted Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) exclusive rights to develop, manufacture, and commercialize RBD7022 in mainland China, Hong Kong, and Macau.

Welcome to contact us to explore
collaboration opportunities